Cellectis (CLLS) Other Working Capital Changes (2015 - 2026)
Cellectis (CLLS) posted quarterly Other Working Capital Changes of $965000.0 for Q1 2026, up 14.47% year-over-year from $843000.0 in Q1 2025, and up 753.98% quarter-over-quarter from $113000.0 in Q4 2025.
Cellectis (CLLS) Other Working Capital Changes (2015 - 2026) Analysis & Trends
Cellectis' Other Working Capital Changes history runs 13 years deep, the most recent figure standing at $965000.0 for Q1 2026.
- In Q1 2026, Other Working Capital Changes rose 14.47% year-over-year to $965000.0; the TTM figure through Mar 2026 stood at $965000.0 (up 14.47% YoY), while the FY2025 annual figure was $1.2 million, up 162.35% from the prior year.
- Other Working Capital Changes for Q1 2026 stood at $965000.0, up from $113000.0 in the prior quarter.
- The five-year high for Other Working Capital Changes was $9.5 million in Q1 2025, with the low at -$130.1 million in Q2 2025.
- The 5-year median for Other Working Capital Changes is -$216500.0 (2022), against an average of -$25.0 million.
- The sharpest annual moves came in 2023 and 2024: Other Working Capital Changes soared 183.97% in 2023, then slumped 268.8% in 2024.
- Cellectis' Other Working Capital Changes stood at $237000.0 in 2022, then jumped by 183.97% to $673000.0 in 2023, then plunged by 268.8% to -$1.1 million in 2024, then soared by 109.95% to $113000.0 in 2025, then jumped by 753.98% to $965000.0 in 2026.
- Business Quant data shows CLLS's Other Working Capital Changes at $965000.0 in Q1 2026, $113000.0 in Q4 2025, and $1.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Cellectis | 306.61 Mn | 120.95 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -78.00 Mn |
| Mar 31, 2026 | -78.00 Mn |
| Mar 31, 2026 | -78.00 Mn |
| Sep 30, 2025 | -2.76 Mn |
| Sep 30, 2025 | -2.76 Mn |
| Sep 30, 2025 | -2.76 Mn |
| Jun 30, 2025 | -130.10 Mn |
| Jun 30, 2025 | -130.10 Mn |
| Jun 30, 2025 | -130.10 Mn |
| Mar 31, 2025 | 9.49 Mn |
| Mar 31, 2025 | 9.49 Mn |
| Mar 31, 2025 | 9.49 Mn |
| Sep 30, 2024 | 8.28 Mn |
| Sep 30, 2024 | 8.28 Mn |
| Sep 30, 2024 | 8.28 Mn |
| Jun 30, 2024 | -105.39 Mn |
| Jun 30, 2024 | -105.39 Mn |
| Jun 30, 2024 | -105.39 Mn |
| Mar 31, 2024 | -1.69 Mn |
| Mar 31, 2024 | -1.69 Mn |